Gynecologic Oncology: Recent Advances and Future Perspectives

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 685

Special Issue Editors


E-Mail Website
Guest Editor
Second Department of Obstetrics and Gynecology, “Aretaieion” Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
Interests: gynecology; gynecologic oncology; peritoneal surface oncology; laparoscopy
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Division of Experimental Surgery and Surgical Research, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, Greece
Interests: gynecology; gynecologic oncology; biomarkers in gynecology; obstetrics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The landscape of gynecologic cancer treatment has dramatically changed over the past few years. Surgical advances, along with the advent of PARP inhibitors, antiangiogenic therapies, and the innovations of genomics and molecular markers, have opened the door to a potential “Golden Era” of gynecologic cancer treatment.

This Special Issue will provide an extensive overview of the latest advances in the  detection, prevention, diagnosis, and treatment of gynecologic malignancies, with particular interest in molecular markers, novel surgical techniques, and advances in established chemotherapy regimens, immunotherapy, and the latest targeted therapies. For this Special Issue of Life, entitled “Gynecologic Oncology: Recent Advances and Future Perspectives”, we seek contributions in the form of original research articles or reviews on all of the potential fields of gynecologic oncology.

Prof. Dr. Theodoros A. Panoskaltsis
Dr. Alkis Matsas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecologic cancer

  • gynecologic oncology
  • biomarkers in gynecology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

13 pages, 784 KiB  
Systematic Review
The Impact of Salvage Radiotherapy in Recurrent Endometrial Cancer: A Review Focusing on Early-Stage, Endometrial Cancer Locoregional Relapses
by Emmanouil Maragkoudakis, Theodoros Panoskaltsis, Kitty Pavlakis, Maria Grenzelia, Evangelia Kavoura, Georgios Papageorgiou, Ioannis Georgakopoulos, Andromachi Kougioumtzopoulou, Efrosyni Kypraiou, Nikolaos Trogkanis, Evangelos Maragkoudakis, Vassilis Kouloulias and Anna Zygogianni
Life 2025, 15(7), 1013; https://doi.org/10.3390/life15071013 - 25 Jun 2025
Abstract
Background/Objectives: Definitive radiotherapy (RT) is a frequently employed salvage option in early-stage, endometrial cancer (EC) loco-regional recurrence patients. Local control (LC) and survival rates are highly variable in the literature. The aim of this review is to assess the impact of modern salvage [...] Read more.
Background/Objectives: Definitive radiotherapy (RT) is a frequently employed salvage option in early-stage, endometrial cancer (EC) loco-regional recurrence patients. Local control (LC) and survival rates are highly variable in the literature. The aim of this review is to assess the impact of modern salvage radiotherapy (SRT) in this group of patients. Methods: A systematic review of the literature was performed, focusing on studies that included EC local recurrence patients receiving SRT after 2000 to reflect advances in radiotherapy techniques. Our report followed the principles as outlined in the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. Nine studies were included in our analysis with a total sample size of 648 patients. Conclusions: SRT offers excellent LC rates in this group of patients with minimal ≥ grade 3 toxicity. Salvage rates are limited by the presence of well-known risk factors for loco-regional relapses, with distant control being the primary mode of failure, resulting in lower survival rates. The decision to omit adjuvant RT should be weighed against the anticipated salvage outcomes in case of relapse. Full article
(This article belongs to the Special Issue Gynecologic Oncology: Recent Advances and Future Perspectives)
Show Figures

Figure 1

Back to TopTop